Printer Friendly

A Case-Control Association Study of RANTES (-28C>G) Polymorphism as a Risk Factor for Parkinson's Disease in Isparta, Turkey.

1. Introduction

Parkinson's disease (PD) affects about 2% of the elderly population and is the second most common neurodegenerative disease after Alzheimer's disease (AD) [1-3]. Clinical manifestations include motor symptoms such as resting tremors, bradykinesia, rigidity, and postural instability as well as nonmotor symptoms such as cognitive decline, depression, olfactory deficits, autonomic dysfunction, and sleep disorders. The pathological process underlying PD is the slow and progressive degeneration and loss of dopaminergic neurons in the substantia nigra projecting to the striatum. It is this loss of dopaminergic neurons that causes most of the motor symptoms. Degeneration is not restricted to nigral dopaminergic neurons but also affects noradrenergic, cholinergic, and serotoninergic neurons as well as neurons in the olfactory bulb and mesenteric system [3]. There are also accumulations and aggregations of misfolded alpha-synucleins. Neuron loss and intracellular alpha-synucleins containing inclusions (Lewy bodies and Lewy neuritis) are the pathological hallmark of PD. Intensive research on the etiopathogenesis of PD is still far from explaining the exact cause of the disease. It is a multifactorial disease with likely genetic and environmental determinants. In a small percentage of PD patients, a definitive link has been shown between specific gene mutations and heritable forms of the disease [4]. Genetic predisposition, environmental toxins, and aging are suggested to be the likely key factors in the initiation and progression of the disease [5]. Oxidative stress, mitochondrial dysfunction, excitotoxicity, accumulation of altered proteins, and apoptosis have been implicated as cellular and molecular mechanisms that might be responsible for neuronal degeneration in PD [3]. Results of postmortem and in vivo studies in patients and studies in animal models suggest that neuroinflammation might also contribute to neuronal degeneration [3-10]. The following symptoms in PD patients indicate that there are neuroinflammatory processes in the affected brain regions: the presence of activated microglial cells, reduced density of astrocytes in the substantia nigra, the presence of cytotoxic T-lymphocytes in the substantia nigra adjacent to blood vessels and dopaminergic neurons, and increased concentrations of tumor necrosis factor-alpha, beta2-microglobulin, transforming growth factor-alpha, transforming growth factor-1beta, interferon gamma, and interleukins-lbeta, 6, and 2 in the striatum, serum, or cerebrospinal fluid [3].

Chemokines are a large family of structurally homologues cytokines that have a role in the mediation and regulation of immune and inflammatory reactions. They are small polypeptides with a molecular weight of 7-15 kDa. Chemokines are classified by the number and location of N-terminal cysteine residues. The two major groups are CC chemokines (beta-chemokines), in which the cysteine residues are adjacent, and CXC chemokines (alpha-chemokines), in which cysteine residues are separated by one amino acid. The genes encoding CXC chemokines are clustered mainly in the 4q13 chromosome locus, whereas the members of CC chemokines are encoded by genes that are located mainly in the 17q112-12 locus [11]. Chemokines are grouped into two main subfamilies according to their function: inflammatory chemokines control the recruitment of leukocytes in inflammation and

tissue injury and homeostatic chemokines fulfill housekeeping functions such as navigating leukocytes to and within secondary lymphoid organs, bone marrow, and thymus during hematopoiesis [12]. During inflammation, CXC chemokines act mainly on neutrophils while CC chemokines act mainly on monocytes, eosinophils, basophils, and lymphocytes [8,13].

Chemokines, in particular inflammatory cytokines, can exert toxic effects via a direct mechanism, through binding to dopaminergic neurons, or by an indirect mechanism, through glial cell activation and the expression of inflammatory factors [3]. Chemokine receptors are seven transmembrane G-protein coupled receptors that chemokines exert their effects by binding them. Chemokines and receptors are inflammatory mediators with broad potential utility as biomarkers. Chemokines MCP-1 (monocyte chemoattractant protein-1; CCL2) and RANTES (regulated on activation normal T-cell expressed and secreted; CCL5) bind to receptors CCR2 and CCR5, respectively. Constitutive expression of chemokines and their receptors are required for migration, differentiation, and proliferation of glial and neuronal cells. Polymorphisms in the 5' regulatory region of the genes may be correlated with their levels [14]. In neuroinflammation, increasing evidence of the CCL2-CCR2 and CCL5-CCR5 axes has been demonstrated. Expressional or functional variations caused by genetic polymorphisms of chemokines and their receptors maybe associated with the predisposition, pathogenesis, and outcomes of human diseases. Disease-associated genetic variants of IL-8/CXCL8 (-251A/T), MCP1/CCL2 (-2518G/A), RANTES/CCL5 (-28C/G), CCR2 (V64I), and CCR5 (-delta32) have been studied in different populations and ethnic groups with PD and late onset AD [6,14].

Genetic predisposition has been suggested as an important factor in the etiopathogenesis of PD. In this study, our aim was to assess whether there were genetically driven differences between the immune responses of healthy people and those with PD, specifically in terms of polymorphisms in chemokines and their receptor genes IL-8, MCP-1, RANTES, CCR2, and CCR5.

2. Materials and Methods

2.1. Patients and Controls. Thirty patients with clinically definite idiopathic PD, according to the PD Society Brain Bank criteria, were enrolled for the study. All patients were recruited from the outpatient clinic of the Neurology Department, Faculty of Medicine, Isparta Suleyman Demirel University (SDU). Isparta is in southwest Turkey, has a low influence of migration from other countries and interregional movement, and has a population of 230,000 that only 5 percent of them are resettlers.

The average age of disease onset was 62.87 years (range 37-77) and the mean duration of disease was 2.37 years (with a range of 1-4) for PD patients (14 male and 16 female). A total of 60 healthy control subjects (18 male and 42 female) were recruited from relatives or friends of patients in general medical clinics. Their mean age was 60.52 years (range 39-80). Healthy control volunteers and patients were excluded from the study if there were any indications of dementia, stroke, secondary parkinsonism, hypertension, neoplastic or hematological disorders, alcoholism, diabetes, recent infection, hepatic or renal insufficiency, or systemic inflammatory disease.

The study was approved by the Research Ethics Committee of Suleyman Demirel University Hospital (07.15.2015/166) and a written consent statement was signed by all subjects.

2.2. Genetic Analyses. A 2 ml blood sample was obtained from patients and control subjects. All DNA samples were obtained using a DNA isolation kit (Thermo Scientific). Genotyping was carried out by the polymerase chain reaction/restriction fragment length polymorphism (PCR-RFLP) method. The PCR-RFLP methods of IL-8 (-251A>T), MCP-1 (-2518A>G), RANTES (-28C>G), CCR-2 (V64I), and CCR-5 (-[DELTA]32) polymorphisms were administered, as shown in Table 1.

To determine the RANTES -28C>G polymorphisms, the relevant area was amplified with PCR and cut with MnlI restriction enzymes. Following the application of the PCRRFLP method for -28C>G polymorphism, 114 + 27 + 20 and 13 bp band patterns were observed in normal individuals (CC), 134 + 27 and 13 bp patterns in homozygous individuals (GG), and 134 + 114 + 27 + 20 and 13 bp patterns in heterozygous individuals (CG), respectively (Figure 1).

2.3. Statistical Analysis. Genotypes were identified based on electrophoresis banding patterns. Allele and genotype frequencies were calculated by simple allele counting. Genotypes and alleles were expressed as numbers and percentages. Each SNP was analyzed with the FINETTI program ( for allele and genotype frequencies (Pearson [chi square] statistics), odds ratios (OR), and p values as well as genetic models such as the homozygous comparison, dominant, recessive, and allele models. When some of the analyzed frequencies were zero, OR was adjusted by Haldane's modification, which adds 0.5 to all cells to accommodate possible zero counts [15]. A Hardy-Weinberg equilibrium of tested groups and Armitage's trend test (ATT) were also calculated using FINETTI. ATT considers genotypes rather than alleles, avoiding a possible bias due to doubling the sample size [16]. The haplotype analysis was performed with the SNPstats program (availability: All statistical tests were conducted at the 0.05 significance level.

3. Results

Genotype and allele frequencies of the relevant polymorphisms were determined from DNA samples of 30 PD patients and 60 control subjects using the PCR-RFLP method. No significant difference was observed between the groups in terms of allele and genotype frequencies of IL-8 (-251A>T), MCP-1 (-2518A>G), CCR-2 (V64I), or CCR-5 (-[DELTA]32) polymorphisms. However, there were significant differences for the RANTES -28C>G polymorphism (Table 2).

The IL-8 (-251A>T) polymorphism was identified in 63.3% of PD patients and 86.6% of control subjects. Nine patients (30%) were heterozygous for the T allele and 10 (33.3%) were homozygous. In the control group, 22 (36.6%) were homozygous and 30 (50%) were heterozygous. There was no statistically significant difference between the patient and control groups in terms of genotype and allele frequency (p = 0.107).

The MCP-1 (-2518A>G) polymorphism was identified in 30% of PD patients and 45% of control subjects. Four PD patients (13.3%) were heterozygous for the G allele and 5 (16.6%) were homozygous, while in the control group, 22 (36.67%) were heterozygous and 5 (8.33%) were homozygous. Still, there was no statistically significant difference between the groups (p = 0.664).

The CCR2 (V641) polymorphism was identified in 23.3% of PD patients and 36.6% of control subjects. Seven (23.3%) PD patients and 22 (36.6%) control subjects were heterozygous for the I allele while no homozygous I allele was detected in either group. The two groups were similar in terms of CCR2 (V641) polymorphism (p = 0.201). Neither group included the CCR5 (-A32) polymorphism.

In terms of the RANTES -28C>G polymorphism, 85% of PD patients expressed C alleles and the remaining G alleles. In the control group, all subjects had C alleles. This allelic difference was found to increase PD risk in our study group at a statistically significant level (OR = 44.456 [CI = 2.540-778.197], p = 0.001). Genotype analysis showed the RANTES -28C>G polymorphism was present in 12.5% of PD patients but it was absent in the control group. Of the PD patients, 3 (10%) were heterozygous and 3 (10%) were homozygous for the G allele. Analysis of possible relationship of genotype frequencies of the RANTES -28C>G polymorphism revealed significant differences in the GG (homozygous) model compared to CC (OR = 17.286 [CI = 0.860-347.237], p = 0.009), in the CG+GG (dominant) model compared to CC (OR = 32, 102 [CI = 1.74-591.937], p = 0.0003), and in the GG (recessive) model compared to CC+GG (OR = 0.065 [CI = 0.003-1.301], p = 0.013). The common odds ratio was 4.580 and the p value was p = 0.0007 in Armitage's trend test. According to the statistical data, the C allele of RANTES -28C>G polymorphism has a protective effect on the disease and the G variant was significantly associated with PD at both allelic and genotypic levels.

Haplotypes with a frequency lower than 5% were excluded from further analysis to minimize loss of power. The most common haplotype was the A, A, C, G, and N alleles of the IL-8 (-251A>T), MCP-1 (-2518A>G), RANTES (-28C>G), CCR-2 (V64I), and CCR-5 (-[DELTA]32) variants. Four haplotypes had a frequency of greater than 5%. The most common haplotype (A-A-C-G-N) was used as a reference haplotype in our analysis (Table 3). This was estimated to have a frequency of 0.429. Using this as the reference haplotype, OR was calculated for each possible haplotype. Haplotype 3 (T-G-C-A-N) was found to be significantly protective for PD (OR = 0.08 [CI = 0.01-0.63], p = 0.019). In addition, the global association of haplotype was also found to be significant (p < 0.0001) between PD patients and control subjects. None of the other haplotypes were found to be significantly associated with PD (Table 3).

4. Discussion

The exact cause of PD is not fully understood. PD's pathogenesis is affected by mechanical and environmental factors, genetic factors, toxins, and oxidative stress. There are no many pathological differences between inherited and sporadic PD. The shared aspects of these forms are the presence of Lewy bodies and the loss of dopaminergic neurons [1,17].

Chemokines are small peptides involved in the recruitment of leukocytes in inflammation and tissue injury and housekeeping functions in leukocyte trafficking during hematopoiesis [18]. In the central nervous system (CNS), chemokine receptors are expressed primarily by microglia, astrocytes, neurons, and endothelial cells [19]. Among chemokines, interleukin-8 is a key mediator associated with inflammation. It plays a key role in neutrophil recruitment and neutrophil degranulation. Interleukin-8 secretion is increased by oxidant stress, which in turn causes the recruitment of inflammatory cells and induces a further increase in oxidant stress mediators, which is already present in dopaminergic neurons in substantia nigra.

Regarding IL-8 (-251A>T) polymorphism, we found no significant difference between PD patients and control subjects. Ross et al. (2004) investigated the relationship of proinflammatory cytokines and Parkinson's disease in an Irish community and found a statistically significant relationship between increased IL-8 levels with IL-8-251A>T polymorphism and the disease [20]. They report that the TT genotype frequency decreased and AT genotype frequency increased significantly in PD patients. However, the difference in genotype frequencies in the PD group did not reach a statistically significant level compared to the control group (p = 0.1068). They suggested that the decrease in TT genotype, which reduces IL-8 production, might play a protective role against PD. In contrast to Ross et al.'s results, TT and TA allele frequencies were about the same in PD patients and control subjects in our study (Table 2).

The monocyte chemoattractant protein-1 (MCP-1) is a member of the C-C chemokine family. It is potent chemotactic factor for monocytes. MCP-1 is produced by many cells including astrocytic, monocytic, and microglial cells. Nishimura et al. (2003) reported a relationship between the MCP-1 -2518A>G polymorphism and PD. The MCP-1 polymorphism was found in 52.5% of 171 patients; 71 patients (42%) were homozygous and 80 (47%) were heterozygous for the G allele. It was concluded that -2518A>G polymorphism increases the expression of MCP-1 and causes higher microglia activation, which might be effective during the early appearance of PD symptoms [21]. In another neurodegenerative disease, Alzheimer's disease, Pola et al. (2004) showed a relationship with the MCP-1 polymorphism [22]. However, Huerta et al. (2004) and Gao et al. (2015) found no significant difference in the distribution of MCP-1 when compared to control subjects [19,23]. In our study, the difference was not statistically significant, although the percentage of those with MCP-1 -2518A>G polymorphism in the control group outnumbered those in the patient group (Table 2).

CCR2 is a receptor for monocyte chemoattractant factor and mediates monocyte chemotaxis. CCR5 is a beta-chemokine receptor predominantly expressed in T-cells, macrophages, dendritic cells, and microglia. It is crucial for chemokine ligand binding and HIV coreceptor activity. We did not observe any significant difference between PD patients and control subjects for CCR2 and CCR5 genotypes (Table 2). Huerta et al. reported similar findings, not only in PD patients but also in Alzheimer's disease patients [19].

RANTES is a selective attractant for memory T-lymphocytes and monocytes and a ligand for CCR5. The NF-[kappa]B pathway is known to work in association with the RANTES promoter region [24]. RANTES -403G/A and -28C/G polymorphisms in the promoter region cause a greater expression of RANTES. These RANTES polymorphisms were suggested to be effective in several autoimmune diseases [25, 26]. Studies reporting increased serum RANTES levels in association with IL-15, IL-8, and MCP-1 in PD patients suggest that the dysregulation in the peripheral cytokine network might be related to the pathogenesis and underlying neurodegeneration [19, 27, 28]. In addition, RANTES serum levels were reported to correlate with disease severity [29, 30].

In this study, we observed RANTES -28C>G polymorphism in 12.5% of PD patients. Of the patient group, 85% expressed C alleles and the rest expressed G alleles. All the control subjects had C alleles. This allele difference in PD patients was found to increase PD risk at a statistically significant level (Table 2). Analysis of possible relationships between genotype frequencies of RANTES -28C>G polymorphism revealed that the C allele had a protective effect on the disease and that the G variant was significantly associated with PD at both allelic and genotypic levels.

Haplotype analyses further confirmed the role of chemokine receptors in PD development. In our study, between-group differences in haplotype frequencies had a global p value of <0.0001. The 3-SNP haplotype T-G-C-A-N was statistically significant (OR = 0.08 [CI = 0.01-0.63], p = 0.019). The frequency of haplotype T-G-C-A-N in PD patients (2.28%) was lower than in control subjects (19.2%), suggesting that haplotype T-G-C-A-N was statistically related to PD as a protective haplotype.

This is the first study to evaluate IL-8, MCP-1, RANTES, CCR2, and CCR5 polymorphisms in a Turkish population with PD. Our results suggest that the -28C>G polymorphism in the promoter region of RANTES might increase the protein expression and consequently contribute to the mechanisms underlying inflammation in neurodegeneration. 10.1155/2016/5042604

Competing Interests

The authors have no competing interests to declare.


[1] D. Calne, "A definition of Parkinson's disease," Parkinsonism and Related Disorders, vol. 11, no. 1, pp. S39-S40, 2005.

[2] J. Lester and E. Otero-Siliceo, "Parkinson's disease and genetics," The Neurologist, vol. 12, no. 5, pp. 240-244, 2006.

[3] E. C. Hirsch and S. Hunot, "Neuroinflammation in Parkinson's disease: a target for neuroprotection?" The Lancet Neurology, vol. 8, no. 4, pp. 382-397, 2009.

[4] M. G. Tansey, M. K. McCoy, and T. C. Frank-Cannon, "Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention," Experimental Neurology, vol. 208, no. 1, pp. 1-25, 2007.

[5] T. Nagatsu and M. Sawada, "Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines," Cellular and molecular neurobiology, vol. 26, no. 4-6, pp. 781-802, 2006.

[6] C. K. Glass, K. Saijo, B. Winner, M. C. Marchetto, and F. H. Gage, "Mechanisms underlying inflammation in neurodegeneration," Cell, vol. 140, no. 6, pp. 918-934, 2010.

[7] P. Sinha, N. Ghosh, S. Mitra et al., "Neuroinflammation during Parkinson's disease: key cells and molecules involved in it," in Inflammation: the Common Link in Brain Pathologies, pp. 185-208, Springer, Berlin, Germany, 2016.

[8] E. C. Hirsch, T. Breidert, E. Rousselet, S. Hunot, A. Hartmann, and P. P. Michel, "The role of glial reaction and inflammation in Parkinson's disease," Annals of the New York Academy of Sciences, vol. 991, pp. 214-228, 2003.

[9] S. H. Mehta and C. M. Tanner, "Role of neuroinflammation in parkinson disease: the enigma continues," Mayo Clinic Proceedings, vol. 91, no. 10, pp. 1328-1330, 2016.

[10] A. De Virgilio, A. Greco, G. Fabbrini et al., "Parkinson's disease: autoimmunity and neuroinflammation," Autoimmunity Reviews, vol. 15, no. 10, pp. 1005-1011, 2016.

[11] M. Caglar and E. Kansu, "Kemokinler, kemokin reseptorleri ve inflamasyon," ANKEM Dergisi, vol. 18, no. 2, pp. 164-168,2004.

[12] W. Wagner, C. Roderburg, F. Wein et al., "Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors," Stem Cells, vol. 25, no. 10, pp. 2638-2647, 2007.

[13] J. Hesselgesser and R. Horuk, "Chemokine and chemokine receptor expression in the central nervous system," Journal of Neurovirology, vol. 5, no. 1, pp. 13-26,1999.

[14] T. Qidwai, "Chemokine genetic polymorphism in human health and disease," Immunology Letters, vol. 176, pp. 128-138, 2016.

[15] J. B. Haldane, "The estimation and significance of the logarithm of a ratio of frequencies," Annals of Human Genetics, vol. 20, no. 4, pp. 309-311, 1956.

[16] P. D. Sasieni, "From genotypes to genes: doubling the sample size," Biometrics, vol. 53, no. 4, pp. 1253-1261,1997.

[17] M. Maral Mouradian, "Recent advances in the genetics and pathogenesis of Parkinson disease," Neurology, vol. 58, no. 2, pp. 179-185, 2002.

[18] V. L. Bryant and C. A. Slade, "Chemokines, their receptors and human disease: the good, the bad and the itchy," Immunology and Cell Biology, vol. 93, no. 4, pp. 364-371, 2015.

[19] C. Huerta, V. Alvarez, I. F. Mata et al., "Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease," Neuroscience Letters, vol. 370, no. 2-3, pp. 151-154, 2004.

[20] O. A. Ross, C. O'Neill, I. M. Rea et al., "Functional promoter region polymorphism of the proinflammatory chemokine IL-8 gene associates with Parkinson's disease in the Irish," Human Immunology, vol. 65, no. 4, pp. 340-346, 2004.

[21] M. Nishimura, S. Kuno, I. Mizuta et al., "Influence of monocyte chemoattractant protein 1 gene polymorphism on age at onset of sporadic Parkinson's disease," Movement Disorders, vol. 18, no. 8, pp. 953-955, 2003.

[22] R. Pola, A. Flex, E. Gaetani et al., "Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer's disease in Italians," Experimental Gerontology, vol. 39, no. 8, pp. 1249-1252, 2004.

[23] L. Gao, H. Tang, K. Nie et al., "MCP-1 and CCR2 gene polymorphisms in Parkinson's disease in a Han Chinese cohort," Neurological Sciences, vol. 36, no. 4, pp. 571-576, 2015.

[24] H. Schmid, A. Boucherot, Y. Yasuda et al., "Modular activation of nuclear factor-xB transcriptional programs in human diabetic nephropathy," Diabetes, vol. 55, no. 11, pp. 2993-3003, 2006.

[25] B. Bai, K. Tanaka, T. Tazawa, N. Yamamoto, and H. Sugiura, "Association between RANTES promoter polymorphism -401A and enhanced RANTES production in atopic dermatitis patients," Journal of Dermatological Science, vol. 39, no. 3, pp. 189-191, 2005.

[26] H. M. Elsaadany, I. K. Afifi, and M. Seliem, "RANTES as a predictor for rheumatoid arthritis susceptibility and activity in Egyptians," Egyptian Rheumatologist, vol. 33, no. 2, pp. 85-91, 2011.

[27] M. Rentzos, C. Nikolaou, E. Andreadou et al., "Circulating interleukin-15 and RANTES chemokine in Parkinson's disease," Acta Neurologica Scandinavica, vol. 116, no. 6, pp. 374-379,2007.

[28] M. Reale, C. Iarlori, A. Thomas et al., "Peripheral cytokines profile in Parkinson's disease," Brain, Behavior, and Immunity, vol. 23, no. 1, pp. 55-63, 2009.

[29] P. Tang, L. Chong, X. Li et al., "Correlation between serum RANTES levels and the severity of Parkinson's disease," Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 208408, 4 pages, 2014.

[30] X. Qin, S. Zhang, C. Cao, Y. P. Loh, and Y. Cheng, "Aberrations in peripheral inflammatory cytokine levels in parkinson disease," JAMA Neurology, vol. 73, no. 11, p. 1316, 2016.

Nilufer Sahin-Calapoglu, (1) Serpil Demirci, (2) Mustafa Calapoglu, (3) and Baris Yasar (1)

(1) Department of Medical Biology, Faculty of Medicine, Siileyman Demirel University, Isparta, Turkey

(2) Department of Neurology, Faculty of Medicine, SUleyman Demirel University, Isparta, Turkey

(3) Department of Biochemistry, Faculty of Science, Suleyman Demirel University, Isparta, Turkey

Correspondence should be addressed to Nilufer Sahin-Calapoglu;

Received 14 August 2016; Revised 10 November 2016; Accepted 21 November 2016

Academic Editor: Jan Aasly

Caption: Figure 1: PCR-RFLP agarose gel electrophoresis of RANTES -28C>G polymorphism (1, 2, and 4 homozygote normal (CC), 3 heterozygote polymorphic (CG), M: 50 bp DNA marker).
TABLE 1: Primer sets, melting temperature (MT), PCR product size,
and genotyping conditions for IL-8 (-251A> T), MCP-1 (-2518A>G),
RANTES (-28C>G), CCR-2 (V64I), and CCR-5 (-A32) genes as well as
single nucleotide polymorphisms (SNPs).

Gene and                      Primer sets                     MT
polymorphism                                             ([degrees]C)

IL-8                F: 5'-GATTCTGCTCTTATGCCTCCA-3'       55[degrees]C
MCP-1                F: 5'-CCGAGATGTTCCCAGCACAG-3'       60[degrees]C
  (-2518 A>G)        R: 5'-CTGCTTTGCTTGTGCCTCTT-3'
RANTES              F: 5'-ACAGAGACTCGAATTTCCGGA-3'       50[degrees]C
  (-28C>G)          R: 5'-CCACGTGCTGTCTTGATCCTC-3'
CCR-2 (V64I)      F: 5'-GGATTGAACAAGGACGCATTTCCCC-3'     63[degrees]C
CCR-5               F: 5' -CCTGGCTGTCGTCCATGCTG-3'       57[degrees]C

Gene and         PCR product   Restriction       Homozygote
polymorphism      size (bp)      enzyme         normal (bp)

IL-8               816 bc         MfeI           296 + 520
  (-251 A>T)
MCP-1              930 bc         PvuII             930
  (-2518 A>G)
RANTES             187 bc         MnII       114 + 27 + 20 + 13
CCR-2 (V64I)       380 bc         FakI              380
CCR-5              735 bc         EcoRI          403 + 332

Gene and            Homozygote
polymorphism     polymorphic (bp)

IL-8                   810
  (-251 A>T)
MCP-1               708 + 222
  (-2518 A>G)
RANTES            134 + 27 + 13
CCR-2 (V64I)        215 + 165
CCR-5                371+ 332

TABLE 2: Genotype and allele frequencies of IL-8 (-251A>T), MCP-1
(-2518A>G), RANTES (-28C>G), CCR-2 (V64I), and CCR-5 (-[DELTA]32)
polymorphisms. Statistically significant values are in bold (HWE:
Hardy-Weinberg equilibrium, MAF: minor allele frequency, OR: odds
ratio, and 95% CI: 95% confidence interval).

Polymorphism    Groups    Genotypes                     HWE
                                                     (p value)

IL-8                      AA       AT       TT

               Case       11       9        10         0.032
               (n = 30)   (0,36)   (0,30)   (0,33)
               Control    8        30       22         0.787
               (n = 60)   (0,13)   (0,50)   (0,37)

                          AA       AG       GG

MCP-1          Case       21       4        5          0.002
(-2518A/G)     (n = 30)   (0,70)   (0,13)   (0,17)
               Control    33       22       5          0.74
               (n = 60)   (0,55)   (0,37)   (0,08)

RANTES                    CC       CG       GG

               Case       24       3        3          0.007
               (n = 30)   (0,80)   (0,10)   (0,10)
               Control    60       0        0          0.001
               (n = 60)   (1,00)   (0,00)   (0,00)

CCR2                      GG       GA       AA

               Case       23       7        0          1.000
               (n = 30)   (0,77)   (0,23)   (0,00)
               Control    38       22       0          0.185
               (n = 60)   (0,63)   (0,37)   (0,00)

CCR5                      NN       ND       DD

               Case       30       0        0          0,001
               (n = 30)   (1,00)   (0,00)   (0,00)
               Control    60       0        0          0,001
               (n = 60)   (1,00)   (0,00)   (0,00)

Polymorphism    Groups     MAF    Association       Allele

IL-8                                              A versus T

               Case       0.483      Case            0.582
               (n = 30)             versus       [0.311-1.087]
               Control    0.617     control        p = 0.088
               (n = 60)

                                                  A versus G

MCP-1          Case       0.233                      0.837
(-2518A/G)     (n = 30)              Case        [0.406-1.723]
               Control    0.267     versus         p = 0.629
               (n = 60)             control

RANTES                                            C versus G

               Case       0.150      Case           44.456
               (n = 30)             versus      [2.540-778.197]
               Control    0.000     control       p = 0.001#
               (n = 60)

CCR2                                              G versus A

               Case       0.117      Case            0.588
               (n = 30)             versus       [0.236-1.467]
               Control    0.183     control        p = 0.251
               (n = 60)

CCR5                                              N versus D

               Case       0,000      Case            1.992
               (n = 30)             versus      [0.039-101.604]
               Control    0,000     control        p = 1.000
               (n = 60)

Polymorphism    Groups    Genetic model (OR [95% CI] Ip value)

                               Homozygous            Dominant

IL-8                          AA versus TT       AA versus AT + TT

               Case              0.331                 0.266
               (n = 30)   C.I. = [0.102-1.074]     [0.093-0.760]
               Control         p = 0.061            p = 0.011#
               (n = 60)

                              AA versus GG       AA versus AG + GG

MCP-1          Case              1.571                 0.524
(-2518A/G)     (n = 30)      [0.405-6.092]         [0.206-1.330]
               Control         p = 0.511             p = 0.171
               (n = 60)

RANTES                        CC versus GG       CC versus CG + GG

               Case              17.286               32.102
               (n = 30)     [0.860-347.237]       [1.741-591.937]
               Control         p = 0.009#           p = 0.001#
               (n = 60)

CCR2                          GG versus AA       GG versus GA + AA

               Case              1.638                 0.526
               (n = 30)      [0.031-85.372]        [0.194-1.423]
               Control         p = 1.000             p = 0.202
               (n = 60)

CCR5                          NN versus DD       NN versus ND + DD

               Case              1.984                 1.984
               (n = 30)     [0.038-102.405]       [0.038-102.405]
               Control         p = 1.000             p = 1.000
               (n = 60)

Polymorphism    Groups      Genetic model     Armittages
                            (OR [95% CI]      trend test
                              Ip value)


IL-8                      AA + AT versus TT   Common odds
(-251A/T)                                      ratio and
                                                p value

               Case             1.158            0,605
               (n = 30)     [0.460-2.914]      p = 0.106
               Control        p = 0.755
               (n = 60)

                          AA + AG versus GG   Common odds
                                               ratio and
                                                p value

MCP-1          Case             0.455            1.032
(-2518A/G)     (n = 30)     [0.121-1.713]      p = 0.664
               Control        p = 0.236
               (n = 60)

RANTES                    CC + CG versus GG   Common odds
(-28C/G)                                       ratio and
                                                p value

               Case             0.065            4.580
               (n = 30)     [0.003-1.301]     p = 0.0007#
               Control       p = 0.013#
               (n = 60)

CCR2                      GG + GA versus AA   Common odds
(V64I)                                         ratio and
(+190G/A)                                       p value

               Case             0.504
               (n = 30)    [0.010-26.026]        0.526
               Control        p = 1.000        p = 0.202
               (n = 60)

CCR5                      NN+ ND versus DD    Common odds
(-[DELTA]32)                                   ratio and
                                                p value

               Case             0.504             nan
               (n = 30)    [0.010-26.026]       p = nan
               Control        p = 1.000
               (n = 60)

Note: Statistically significant values were indicated with #.

TABLE 3: Five marker haplotype estimates and odds ratio (OR) analysis.

Haplotypes     IL-8        MCP-1       RANTES          CCR2
             (-251A/T)   (-2518A/G)   (-28C/G)   (V64I) (+190G/A)

1                A           A           C              G
2                T           A           C              G
3                T           G           C              A
4                T           G           C              G

Haplotypes       CCR5       Frequency          OR           p value
             (-[DELTA]32)                    95% CI

1                 N           0.429           1.00            --
2                 N           0.317     0.66 (0.24-1.85)     0.43
3                 N           0.141     0.08 (0.01-0.63)#   0.019#
4                 N           0.065     0.58 (0.10-3.45)     0.55
COPYRIGHT 2017 COPYRIGHT 2010 SAGE-Hindawi Access to Research
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Sahin-Calapoglu, Nilufer; Demirci, Serpil; Calapoglu, Mustafa; Yasar, Baris
Publication:Parkinson's Disease
Article Type:Report
Geographic Code:7TURK
Date:Jan 1, 2017
Previous Article:Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.
Next Article:Deep Brain Stimulation in Parkinson's Disease: New and Emerging Targets for Refractory Motor and Nonmotor Symptoms.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |